A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance

Diabetic Medicine

Volumn 13, Issue 4, 1996, Pages 330-336

  Inoue, I ^a   Takahashi, K ^a   Katayama, S ^a   Harada, Y ^a   Negishi, K ^a   Ishii, J ^a   Shibazaki, S ^a   Nagai, M ^a   Kawazu, S ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

75 g OGTT; C peptide; IGT; Predictor; Proinsulin; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; MARKER; PROINSULIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREDICTION;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROINSULIN; REGRESSION ANALYSIS; SECRETORY RATE;

EID: 0029878070     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199604)13:4<330::AID-DIA60>3.0.CO;2-L     Document Type: Article

References (22)

1. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance: the Whitehall study. Lancet 1980; i: 1373-1376.
2. Jarrett RJ, McCartney P, Keen H. The Bedford survey: The year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycemic control and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22: 79-84.
3. Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford Survey (1962-1972): glucose tolerance and diabetes. Diabetologia 1982; 22: 73-78.
4. O'Sullivan JB, Mahan CM. Blood sugar levels, glycosuria, and body weight related to development of diabetes mellitus. J Am Med Assoc 1965; 194: 117-122.
5. Sakaki A, Suzuki T, Horiuchi N. Development of diabetes in Japanese subjects with impaired glucose tolerance: a seven-year follow-up study. Diabetologia 1982; 22: 154-157.
6. Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, Kuzuya N, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984; 26: 44-49.
7. Polonsky K, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin, pitfalls and limitations. Diabetes 1984; 33: 486-494.
8. Inoue I, Takahashi K, Katayama S, Suzuki M, Negishi K, Ishii J, et al. Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance. Diabetes Res Clin Pract 1994; 25: 199-205.
9. Sando M, Lees V, Iwamato T, Ikeuchi M, Kosaka K. Isoproterenol stimulates C-peptide and insulin secretion in diabetic and non-obese normal subjects: decreased hepatic extraction of endogenous insulin in diabetes. J Clin Endocrinol Metab 1980; 51: 1143-1149.
10. Meistas M, Maligolis T, Kowarski AA. Hyperinsulinemia of obesity is due to decreased clearance of insulin. Am J Physiol 1983; 245: E155-E159.
11. Porte DJ, Kahn SE. Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell dysfunction? Diabetes 1988; 38: 1333-1336.
12. Gorden P, Hendricks CM, Roth J. Circulating proinsulin-like component in man: increased proportion in hyperproinsulinemic state. Diabetologia 1974; 10: 469-474.
13. Reaven GM, Chen Y-DI, Hollenbeck CB, Sheu WHH, Ostrega D, Polonsky KS. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab 1993; 76: 44-48.
14. Ward WK, Lacava EC, Paquette TL, Bead JC, Wallum BJ, Porte DJ. Disproportionate elevation of immunoreactive proinsulin in Type 2 (non-insulin-dependent) diabetes mellitus in experimental insulin resistance. Diabetologia 1987; 30: 698-702.
15. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1988; 31; 355-360.
16. Deacon CF, Schleser-Mohr S, Ballmann M, Willms B, Conlon JM, Cre'utzfeldt W. Preferential release of proinsulin relative to insulin in non-insulin-dependent diabetes mellitus. Acta Endocrinol 1988; 119: 549-554.
17. Watanabe Y, Horie H, Hata K, Ono T, Tomono S, Kawazu S. A new radioimmunoassay of human proinsulin (in Japanese). Proceeding for Annual Meeting of Peptide Hormones in Pancreas, Biomedical Research Foundation (Tokyo) 1993; 13: 69-73.
18. Yoshida N, Kuzuya T, Matsuda A, Iwamoto Y. Effect of dietary treatment on serum insulin and proinsulin response in newly diagnosed NIDDM. Diabetes 1989; 38: 262-266.
19. Polonsky KS, Gumbiner B, Ostrega D, Griver K, Tager H, Henry RR. Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss NIDDM. Diabetes 1994; 43: 871-877.
20. Iwamoto Y, Shiraishi I, Kuzuya T, Kumakura S, Awata T, Saito T. Effect of CS-045 treatment on serum proinsulin level in NIDDM (Abstract). Diabetes 1993; 42 (suppl 1): 57A.
21. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, et al. The relationships of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in Type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990; 33: 532-537.
22. Haffner SM, Mykkanen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR. Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetes 1993; 42: 1297-1301.